DOXIMITY INC-CLASS A (DOCS)
US26622P1075 - Common Stock
Taking everything into account, DOCS scores 7 out of 10 in our fundamental rating. DOCS was compared to 41 industry peers in the Health Care Technology industry. Both the health and profitability get an excellent rating, making DOCS a very profitable company, without any liquidiy or solvency issues. DOCS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make DOCS suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
In the past year DOCS had a positive cash flow from operations.
In the past 5 years DOCS has always been profitable.
In the past 5 years DOCS always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 13.67%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DOCS has a better Return On Equity (16.37%) than 100.00% of its industry peers.
DOCS has a Return On Invested Capital of 15.15%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 5.77%.
The last Return On Invested Capital (15.15%) for DOCS is above the 3 year average (12.02%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.67% | ||
| ROE | 16.37% | ||
| ROIC | 15.15% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
1.3 Margins
The Profit Margin of DOCS (31.04%) is better than 100.00% of its industry peers.
DOCS's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 36.14%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DOCS's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 89.35%, DOCS belongs to the top of the industry, outperforming 94.87% of the companies in the same industry.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.14% | ||
| PM (TTM) | 31.04% | ||
| GM | 89.35% |
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
DOCS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for DOCS has been reduced compared to 1 year ago.
Compared to 5 years ago, DOCS has more shares outstanding
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
DOCS has an Altman-Z score of 19.32. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.32, DOCS belongs to the top of the industry, outperforming 97.44% of the companies in the same industry.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.32 |
ROIC/WACC1.54
WACC9.82%
2.3 Liquidity
DOCS has a Current Ratio of 6.20. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.20, DOCS belongs to the top of the industry, outperforming 89.74% of the companies in the same industry.
DOCS has a Quick Ratio of 6.20. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.20, DOCS belongs to the top of the industry, outperforming 89.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.2 | ||
| Quick Ratio | 6.2 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.14%, which is quite impressive.
Measured over the past years, DOCS shows a very strong growth in Earnings Per Share. The EPS has been growing by 81.49% on average per year.
The Revenue has grown by 13.44% in the past year. This is quite good.
The Revenue has been growing by 40.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)30.14%
EPS 3Y81.49%
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)13.44%
Revenue growth 3Y31.96%
Revenue growth 5Y40.87%
Sales Q2Q%6.39%
3.2 Future
The Earnings Per Share is expected to grow by 12.92% on average over the next years. This is quite good.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.90% yearly.
EPS Next Y5.59%
EPS Next 2Y7.32%
EPS Next 3Y11.01%
EPS Next 5Y12.92%
Revenue Next Year8.12%
Revenue Next 2Y8.58%
Revenue Next 3Y9.3%
Revenue Next 5Y10.9%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 29.44, which means the current valuation is very expensive for DOCS.
DOCS's Price/Earnings ratio is rather cheap when compared to the industry. DOCS is cheaper than 87.18% of the companies in the same industry.
When comparing the Price/Earnings ratio of DOCS to the average of the S&P500 Index (28.35), we can say DOCS is valued inline with the index average.
With a Price/Forward Earnings ratio of 27.88, DOCS can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, DOCS is valued a bit cheaper than the industry average as 79.49% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 20.05. DOCS is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.44 | ||
| Fwd PE | 27.88 |
4.2 Price Multiples
82.05% of the companies in the same industry are more expensive than DOCS, based on the Enterprise Value to EBITDA ratio.
74.36% of the companies in the same industry are more expensive than DOCS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.09 | ||
| EV/EBITDA | 20.5 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)5.27
PEG (5Y)N/A
EPS Next 2Y7.32%
EPS Next 3Y11.01%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DOXIMITY INC-CLASS A
NYSE:DOCS (6/28/2024, 7:04:00 PM)
After market: 27.97 0 (0%)27.97
+0.14 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.19B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.44 | ||
| Fwd PE | 27.88 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)5.27
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.67% | ||
| ROE | 16.37% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 36.14% | ||
| PM (TTM) | 31.04% | ||
| GM | 89.35% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.2 | ||
| Quick Ratio | 6.2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)30.14%
EPS 3Y81.49%
EPS 5Y
EPS Q2Q%
EPS Next Y5.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)13.44%
Revenue growth 3Y31.96%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y